Natera Responds to Misleading Press Release by CareDx

AUSTIN, Texas, Aug. 7, 2023 — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today responded to a misleading press release from CareDx mischaracterizing a stipulated order entered by the United States District Court for the District of Delaware.

This is not a new decision, simply the Court’s entry of an order agreed upon by both parties, implementing a previous ruling in favor of Natera. That ruling held that CareDx was not entitled to any damages, reducing a $45 million jury verdict to $0. Contrary to CareDx’s misleading public statements, the Court also ruled that CareDx showed no evidence that Natera deceived any member of the transplant community. The advertisements at issue in this case have been obsolete for several years, and today’s order has no impact on Natera’s current advertising. Most importantly, the jury’s verdict never called into question the performance of the Prospera™ test or peer-reviewed data.

CareDx also again fails to acknowledge that the jury found it liable for false advertising in this case and that its Chief Medical Officer misled the transplant community about CareDx’s involvement in a clinical study it claimed was independent. Evidence presented at trial showed CareDx funded and participated in the drafting of the paper. In fact, today’s order enjoins CareDx from misrepresenting its involvement with and funding of that study.

Regardless of the misleading statements made by CareDx, Natera is gratified by the strong support it has received from the transplant community. The company remains focused on addressing critical unmet needs for patients and their families in pursuit of better outcomes and continuing to drive innovation supported by published evidence, including many peer-reviewed papers demonstrating the clinical utility of Prospera.